Sanofi SA on Thursday backed its yearly guidance and reported higher sales for the first quarter, driven by its specialty care and vaccine businesses.
The French pharma company confirmed that it expects 2023 business earnings per share—a key metric—to grow low-single digit at constant exchange rates, barring unforeseen major adverse events.
Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Read More
Stephania Byron
